Evidence map›Paper›PMID 30355799›Full record

ArticleScience translational medicine2018

Suppression of stromal-derived Dickkopf-3 (DKK3) inhibits tumor progression and prolongs survival in pancreatic ductal adenocarcinoma.

Liran Zhou, Hongmei Husted, Todd Moore, Mason Lu, Defeng Deng, Yan Liu, Vijaya Ramachandran, Thiruvengadam Arumugam, Christof Niehrs, Huamin Wang and 8 more

Abstract read
In one paragraph

Article in Science translational medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
1.5field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 40 citations in OpenAlex.

  1. Ad-SGE-DKK3 Gene Therapy Overcomes Resistance to Immune Checkpoint Blockade in Pleural Mesothelioma.Clinical cancer research : an official journal of the American Association for Cancer Research · 2025
    Trial
  2. Article
  3. Article
  4. Review
  5. Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 2 institutions in 2 countries.

Liran ZhouDepartment of Surgical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.ORCID 0000-0002-0192-4614
Hongmei HustedDepartment of Surgical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.ORCID 0000-0002-7782-6746
Todd MooreDepartment of Surgical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Mason LuDepartment of Surgical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Defeng DengDepartment of Cancer Biology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Yan LiuDepartment of Cancer Biology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.ORCID 0000-0002-1518-7264
Vijaya RamachandranDepartment of Cancer Biology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Thiruvengadam ArumugamDepartment of Cancer Biology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Christof NiehrsDivision of Molecular Embryology, DKFZ-ZMBH Alliance, Deutsches Krebsforschungszentrum (DKFZ), 69120 Heidelberg, Germany.
Huamin WangDepartment of Pathology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Paul ChiaoDepartment of Molecular and Cellular Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Jianhua LingDepartment of Molecular and Cellular Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Michael A CurranDepartment of Immunology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Anirban MaitraDepartment of Pathology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.ORCID 0000-0001-7923-9978
Mien-Chie HungDepartment of Molecular and Cellular Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.ORCID 0000-0003-4317-4740
Jeffrey E LeeDepartment of Surgical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.ORCID 0000-0001-6010-5590
Craig D LogsdonDepartment of Cancer Biology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Rosa F HwangDepartment of Surgical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. rhwang@mdanderson.org.ORCID 0000-0002-3103-6511
The University of Texas MD Anderson Cancer Center · USGerman Cancer Research Center · DE

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Scott Kopetz · 1985 to 2026
$290.8M
Stromal Periostin in Pancreatitis and Pancreas CancerK08CA138912 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI HWANG, ROSA F. · 2009 to 2013
$853k
Inhibition of Stromal-Derived DKK3 to Enhance the Response of Pancreatic Cancer to ImmunotherapyR21CA218495 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI HWANG, ROSA F. · 2017 to 2018
$383k
NCI NIH HHS K08 CA138912NCI NIH HHS P30 CA016672NCI NIH HHS R21 CA218495
6 · The paper itself

Abstract

Pancreatic ductal adenocarcinoma (PDAC) has a dismal prognosis, and it is unclear whether its stromal infiltrate contributes to its aggressiveness. Here, we demonstrate that Dickkopf-3 (DKK3) is produced by pancreatic stellate cells and is present in most human PDAC. DKK3 stimulates PDAC growth, metastasis, and resistance to chemotherapy with both paracrine and autocrine mechanisms through NF-κB activation. Genetic ablation of DKK3 in an autochthonous model of PDAC inhibited tumor growth, induced a peritumoral infiltration of CD8

Indexed as

Disease ProgressionAdaptor Proteins, Signal TransducingAnimalsAntibodies, NeutralizingAutocrine CommunicationCarcinoma, Pancreatic DuctalCell Line, TumorChemokinesDeoxycytidineDisease Models, AnimalDrug Resistance, NeoplasmGemcitabineGene SilencingHumansImmunotherapyIntercellular Signaling Peptides and ProteinsAdaptor Proteins, Signal TransducingAntibodies, NeutralizingChemokinesDeoxycytidineDKK3 protein, humanGemcitabineIntercellular Signaling Peptides and ProteinsNF-kappa B

Identifiers

PMID30355799
PMCPMC6752716
OpenAlexW2898406892

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.